4-pentyl-1H-benzimidazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-pentyl-1H-benzimidazol-2-amine
• 化学式: C₁₂H₁₇N₃
• 分子量: 203.28
• InChiKey: IEZOIDSJWKNKOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS<br/>[FR] INHIBITEURS DE KINASE DIFLUORODIOXALANE-AMINOBENZIMIDAZOLE POUR LE TRAITEMENT D'UN CANCER, D'UNE INFLAMMATION AUTO-IMMUNE ET DE TROUBLES DU SNC
  申请人：4SC DISCOVERY GMBH

  公开号：WO2014001464A1

  公开（公告）日：2014-01-03

  The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, (I) wherein A is a bond, alkyl or alkoxy optionally substituted with one or more R" as defined herein, *-N(R"')CO-, *-CON(R"')-, *-N(R'")CON(R"')-, -S-, -SO-, *-N(R'")-, *-N(R'")CO-, *-CON(R'")-, -CO-, *-COO-, *-OOC-, *-S02N(R"')-, -S02, or *-N(R"')-SO2-, wherein R"' is as defined herein and * specifies the point of attachment to X; X is aryl, cycloalkyl, aralkyl, heterocyclyl or heteroaryl, which may be substituted with one or more Rx further described herein; L is a bond or *-N(RN)CO-, *-CON(RN)-, *-N(RN)-, *-C=N(RN)-, *-N(RN)-alkyI-, *-alkyl-N(RN)-, *-N(RN)CON(RN)-, *-CO-, *-S02-, alkyl, *-alkyl-0-alkyl-, *-NCO-CH=CH-, *-CH=CH-CONH-, * -S02N(RN)-, *-N(RN)S02-, or heterocyclyl, wherein * specifies the point of attachment to X; Y is H, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heteroaryl, which may be substituted with one or more RY further described herein; and R and RN are further described herein; as well as their use as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, CNS disorders, sleeping disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.

  该发明涉及一般式(I)的化合物或其生理功能衍生物、溶剂或盐，其中(I)中A是键，烷基或烷氧基，可选择地用一个或多个如下所定义的R"取代，*-N(R"')CO-，*-CON(R"')-，*-N(R'")CON(R"')-，-S-，-SO-，*-N(R'")-，*-N(R'")CO-，*-CON(R'")-，-CO-，*-COO-，*-OOC-，*-S02N(R"')-，-S02，或*-N(R"')-SO2-，其中R"'如此定义，*指定连接到X的点；X是芳香族，环烷基，芳基烷基，杂环烷基或杂芳基，可用一个或多个Rx进一步描述；L是键或*-N(RN)CO-，*-CON(RN)-，*-N(RN)-，*-C=N(RN)-，*-N(RN)-烷基-，*-烷基-N(RN)-，*-N(RN)CON(RN)-，*-CO-，*-S02-，烷基，*-烷基-0-烷基-，*-NCO-CH=CH-，*-CH=CH-CONH-，*-S02N(RN)-，*-N(RN)S02-，或杂环烷基，其中*指定连接到X的点；Y是H，烷基，芳基，芳基烷基，环烷基，杂环烷基或杂芳基，可用一个或多个RY进一步描述；R和RN在此进一步描述；以及它们作为药物的用途，包括它们的药物组合物，治疗或预防涉及其管理的医疗状况的方法，以及在制造用于治疗或预防医疗状况的药物中的用途，特别是自身免疫性炎症性疾病、中枢神经系统疾病、睡眠障碍或包括癌症在内的增殖性疾病。该发明还涉及一种特定的制备上述化合物的过程。
• THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
  申请人：Northwestern University

  公开号：US20170305901A1

  公开（公告）日：2017-10-26

  Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

  揭示了治疗与混合系谱白血病基因（MLL-r）重排相关的癌症的方法，包括MLL-r白血病。这些方法通常包括给予治疗量的一个或多个治疗剂，其抑制白介素-1信号通路的一个或多个成员的生物活性，例如白介素-1受体相关激酶4（IRAK4）的抑制剂。
• BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS
  申请人：4SC DISCOVERY GMBH

  公开号：US20150158878A1

  公开（公告）日：2015-06-11

  The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, wherein A, X, L, Y, R, and R N are as defined herein. The invention further relates to the use of the compounds of formula (I) as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, CNS disorders, sleeping disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.

  本发明涉及一种通式(I)的化合物或其生理功能衍生物、溶剂或盐，其中A、X、L、Y、R和RN如本文所定义。本发明还涉及将通式(I)的化合物用作药物，包括它们的制药组合物，以及治疗或预防需要其给药的医疗状况的方法，以及将其用于制造治疗或预防医疗状况的药物，尤其是自身免疫炎症性疾病、中枢神经系统疾病、睡眠障碍或增殖性疾病，包括癌症。本发明还涉及一种特定的制备上述化合物的方法。
• Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
  申请人：Northwestern University

  公开号：US10059708B2

  公开（公告）日：2018-08-28

  Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

  所公开的是治疗与混合系白血病基因（MLL-r）重排相关的癌症（包括 MLL-r 白血病）的方法。这些方法通常包括施用治疗量的一种或多种治疗剂，这些治疗剂可抑制白细胞介素-1 信号通路的一个或多个成员的生物活性，如白细胞介素-1 受体相关激酶 4（IRAK4）的抑制剂。
• Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
  申请人：Northwestern University

  公开号：US10640502B2

  公开（公告）日：2020-05-05

  Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

  所公开的是治疗与混合系白血病基因（MLL-r）重排相关的癌症（包括 MLL-r 白血病）的方法。这些方法通常包括施用治疗量的一种或多种治疗剂，这些治疗剂可抑制白细胞介素-1 信号通路的一个或多个成员的生物活性，如白细胞介素-1 受体相关激酶 4（IRAK4）的抑制剂。